01 / FULL THERAPEUTIC MATRIX
25 mg Controlled-Release Action
Polymer-coated matrix delivers complete 25 mg paroxetine release in the small intestine, providing maximum SERT occupancy with minimal gastric nausea.
Blessme · Antidepressants & Anxiolytics
Paroxetine CR + Clonazepam Tablets - PAXOTIN-CR-FORTE
PAXOTIN-CR-FORTE is a high-strength controlled-release neuropsychiatric formulation combining Paroxetine Hydrochloride IP equivalent to Paroxetine 25 mg (CR) with Clonazepam IP 0.5 mg by Blessme, Dellwich Lifescience LLP. Engineered for severe refractory major depressive disorder, debilitating panic disorder with agoraphobia, and severe anxiety states, providing full therapeutic 24-hour serotonergic restoration with immediate GABAergic anti-panic coverage.
Full 25 mg CR Dose
Narcotic / Schedule H
Pan-India Supply
Product SpecificationsAbout Paroxetine CR + Clonazepam
About Paroxetine CR + Clonazepam
(PAXOTIN-CR-FORTE)
Detailed pharmaceutical specifications, active API monograph compliance, full-strength controlled-release matrix synergy, and 10x10 aluminium strip packaging details for PAXOTIN-CR-FORTE.
Blessme · Antidepressant & Anxiolytic
Paroxetine CR + Clonazepam - PAXOTIN-CR-FORTE
PAXOTIN-CR-FORTE provides full-strength 25 mg Paroxetine CR paired with 0.5 mg Clonazepam. Formulated for patients suffering from severe depression complicated by frequent panic attacks, intense somatic anxiety, and persistent insomnia requiring maximal therapeutic effect.
25 mg Controlled-Release Paroxetine Delivers Maximum SERT Occupancy0.5 mg Clonazepam Shuts Down Severe Panic & Somatic Terror Specialized Polymeric Coating Prevents Stomach Irritation 10x10 Aluminium Foil Strip Format for Maximum Protection Strict Indian Pharmacopoeia Quality Standards
- Product Brand Name
- PAXOTIN-CR-FORTE
- Active Pharmaceutical Ingredients
- Paroxetine HCl IP eq. to Paroxetine 25 mg (CR) + Clonazepam IP 0.5 mgVerified IP
- Therapeutic Class
- High-Strength Controlled-Release SSRI Antidepressant & Benzodiazepine Anxiolytic
- Dosage Form
- Controlled-Release Film-Coated Tablet
- Strength Formulation
- 25 mg Paroxetine CR + 0.5 mg Clonazepam (Full Therapeutic Maintenance Strength)
- Packaging Standard
- 10x10 Aluminium Foil Strips (100 Tablets per Box)
- Regulatory Category
- Narcotic Drug
- Marketing Division
- Blessme · Neuro & Psychiatric Products
- Manufacturing Standard
- WHO-GMP & ISO 9001:2015 Certified Clean-Room Compression
- Storage Condition
- Store below 25°C in a dry place. Protect from light and moisture.
- Country of Origin
- India
Clinical & Commercial MonographParoxetine CR + Clonazepam Tablet & PAXOTIN-CR-FORTE
Paroxetine CR + Clonazepam Tablet & PAXOTIN-CR-FORTE
Complete Medical & Supply Guide
In-depth pharmacological evaluation of Paroxetine CR 25 mg + Clonazepam 0.5 mg tablets, marketed as PAXOTIN-CR-FORTE by Blessme (Dellwich Lifescience LLP). Covers full-strength panic control, refractory depression treatment, and pharmaceutical supply across India.
What is PAXOTIN-CR-FORTE (Paroxetine CR 25 mg + Clonazepam 0.5 mg)?
PAXOTIN-CR-FORTE is a full-strength oral neuropsychiatric formulation combining an extended-release enteric formulation of the potent SSRI (Paroxetine CR 25 mg) with a high-affinity positive GABA_A modulator (Clonazepam 0.5 mg).
When patients suffer from severe treatment-resistant depression or debilitating panic disorder with agoraphobia, lower doses may fail to achieve clinical remission. PAXOTIN-CR-FORTE provides the definitive 25 mg maintenance dose with immediate high-potency anxiolytic coverage via Clonazepam from day one.
Clinical Uses & Evidence-Based Indications
Approved neurological and psychiatric indications for PAXOTIN-CR-FORTE include:
- Severe Major Depressive Disorder (MDD): Provides definitive 25 mg maintenance serotonergic therapy.
- Panic Disorder with Agoraphobia: Aborts recurrent panic attacks and eliminates anticipatory avoidance.
- Refractory Generalized Anxiety Disorder: Controls severe generalized worry failing lower-dose therapies.
- Severe Social Anxiety Disorder (Social Phobia): Overcomes severe social avoidance and public distress.
- Obsessive-Compulsive Traits Comorbid with Panic: Paroxetine 25 mg provides robust antiobsessional coverage.
Neurochemical Mechanism of Action: Serotonergic & GABAergic Synergy
Paroxetine 25 mg acts as a highly selective and potent inhibitor of the serotonin transporter (SERT). By preventing serotonin reuptake across 24 continuous hours, it steadily elevates synaptic 5-HT concentrations, promoting brain-derived neurotrophic factor (BDNF) expression and reversing stress-induced atrophy in the hippocampus and prefrontal cortex over 2 to 4 weeks.
Simultaneously, Clonazepam 0.5 mg acts immediately as a positive allosteric modulator on the GABAA receptor complex. By increasing chloride influx, it hyperpolarizes limbic neurons, immediately terminating acute panic attacks, motor restlessness, and severe autonomic surges from the very first dose.
PAXOTIN-CR-FORTE vs. PAXOTIN-CR-PLUS
Clinical selection criteria between the two strengths:
- PAXOTIN-CR-PLUS (12.5 mg + 0.5 mg): Starting titration formulation for therapy initiation and mild-to-moderate depression-panic overlap.
- PAXOTIN-CR-FORTE (25 mg + 0.5 mg): Definitive maintenance therapy for patients requiring full 25 mg Paroxetine efficacy for severe depression, severe panic disorder, or social phobia.
- Controlled Release: Both utilize enteric matrix coating to prevent gastric irritation and nausea.
Dosage Guidelines & Administration Method
PAXOTIN-CR-FORTE must be taken strictly in accordance with medical advice:
- Administration Time: Typically 1 tablet once daily, preferably in the morning or at bedtime with food.
- Swallow Whole: Take with water; do not crush, split, or chew the tablet.
- With or After Food: Administration with meals further reduces potential mild nausea.
- Gradual Tapering: Discontinue gradually under psychiatric guidance to avoid rebound anxiety and discontinuation reactions.
Critical Safety Warning - Schedule H / Narcotic Controlled Substance
PAXOTIN-CR-FORTE contains Clonazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Contraindicated with monoamine oxidase inhibitors (MAOIs). Dispensed strictly against a valid medical prescription.
Quality & Production
Pharmaceutical Quality Assurance & Compliance
PAXOTIN-CR-FORTE is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
02 / PROTECTIVE PACKAGING
High-Barrier Aluminium Strip
Tamper-evident 10x10 aluminium-aluminium foil packaging shields active APIs against atmospheric moisture and thermal degradation for extended shelf stability.
03 / PHARMACOPOEIA DOSSIERS
COA & Dissolution Profiles
Every batch is verified through authenticated Certificates of Analysis (COA), multi-point dissolution profiling, and HPLC active assay validation complying with IP standards.
04 / WHO-GMP COMPLIANCE
Schedule M Manufacturing
Produced in state-of-the-art cleanroom manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Clinical Profile & Precautions
Approved Indications & Regulatory Guidelines
Prescribing guidance, contraindications, and drug interactions for Paroxetine CR 25 mg + Clonazepam 0.5 mg tablets.
Prescription-Only Schedule H / Narcotic Medication Notice
PAXOTIN-CR-FORTE is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Clinical Indications Profile
Approved neurological and psychiatric indications for PAXOTIN-CR-FORTE:
- Severe Major Depressive Disorder: Full-strength serotonergic recovery with minimal nausea.
- Panic Disorder with Agoraphobia: Powerful suppression of recurrent panic crises and fear of public places.
- Refractory GAD: Full-dose control over chronic severe anxiety and somatic agitation.
- Social Phobia (Social Anxiety Disorder): Restores social functioning and reduces anticipatory dread.
Contraindications & Precautions
Key contraindications and monitoring requirements:
- MAOI Interaction: Never use concurrently with MAOIs; observe a 14-day washout period.
- Swallow Whole: Do not split or chew the tablet to preserve the CR matrix.
- Alcohol Prohibition: Dangerous synergism leading to severe hypotension and CNS depression.
- Gradual Discontinuation: Taper slowly under physician direction.
Manufacturing & Marketing
Dellwich Lifescience LLPBlessme · Neuro & Psychiatric Division
About Dellwich Lifescience
Trusted Neuro & Psychiatric Pharmaceutical Manufacturer in Ahmedabad, Gujarat
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including PAXOTIN-CR-FORTE (Paroxetine CR 25 mg + Clonazepam 0.5 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Commercial PartnershipsPAXOTIN-CR-FORTE Supply &
PAXOTIN-CR-FORTE Supply &
Pharmaceutical Distribution
Whether you are seeking PAXOTIN-CR-FORTE for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Exclusive Monopoly PCD Franchise
Secure district-level monopoly marketing rights for PAXOTIN-CR-FORTE and the complete Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Third-Party Contract Manufacturing
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Hospital & Institutional Procurement
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
Blessme · PAXOTIN-CR-FORTE
Why Choose PAXOTIN-CR-FORTE Tablets?
When sourcing Paroxetine CR 25 mg Clonazepam tablets in India, PAXOTIN-CR-FORTE by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
WHO-GMP Certified Purity
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and controlled dissolution.
High-Barrier Aluminium Packaging
Tamper-evident, moisture-resistant aluminium strips protect tablets from ambient humidity and transport friction.
Pan-India Dispatch from Ahmedabad
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Monopoly PCD Franchise Rights
Exclusive district-level franchise rights for PAXOTIN-CR-FORTE and the Blessme portfolio with promotional visual aids.
Comprehensive Regulatory Dossiers
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct Manufacturer Support
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Common Questions
Frequently Asked Questions about PAXOTIN-CR-FORTE
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Paroxetine CR 25 mg + Clonazepam tablets.
What is PAXOTIN-CR-FORTE and what does it contain?
PAXOTIN-CR-FORTE is a full-strength controlled-release oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Paroxetine Hydrochloride IP equivalent to Paroxetine 25 mg (controlled release) and Clonazepam IP 0.5 mg, formulated for severe refractory depression comorbid with acute panic attacks and severe anxiety.
When is PAXOTIN-CR-FORTE prescribed instead of PAXOTIN-CR-PLUS?
PAXOTIN-CR-FORTE contains 25 mg Paroxetine CR (compared to 12.5 mg in PAXOTIN-CR-PLUS). It is prescribed when the patient requires full therapeutic maintenance dosing for severe major depressive disorder, refractory panic disorder with agoraphobia, or severe obsessive-compulsive symptoms.
How does the combination in PAXOTIN-CR-FORTE work?
Paroxetine 25 mg provides potent 24-hour SERT inhibition, restoring core neuroplasticity, mood vitality, and emotional stability over 2 to 4 weeks. Simultaneously, Clonazepam 0.5 mg provides immediate positive GABAergic limbic suppression, aborting acute panic attacks and autonomic anxiety surges from day one.
When should PAXOTIN-CR-FORTE be taken?
Psychiatrists typically advise taking PAXOTIN-CR-FORTE once daily, preferably in the morning with breakfast or at bedtime if Clonazepam-induced sedation is noticeable. Always swallow the tablet whole with water.
Can the tablet be split, crushed, or chewed?
No. PAXOTIN-CR-FORTE must be swallowed whole. Crushing, splitting, or chewing ruptures the enteric polymer barrier, leading to rapid dose dumping of 25 mg Paroxetine, which can cause severe nausea, vomiting, and loss of 24-hour controlled efficacy.
Does PAXOTIN-CR-FORTE cause daytime drowsiness?
Yes. Due to the Clonazepam 0.5 mg component, mild-to-moderate sedation, drowsiness, or lightheadedness can occur, particularly during initial days of therapy. Patients should avoid driving or operating heavy machinery until individual tolerance is established.
Can PAXOTIN-CR-FORTE be stopped suddenly?
No. Abrupt stoppage can precipitate severe discontinuation reactions (dizziness, electric shock sensations, sensory disturbances, insomnia, and rebound panic). Gradual dose tapering under psychiatric direction is mandatory.
Can I drink alcohol while taking PAXOTIN-CR-FORTE?
Alcohol is strictly prohibited. Combining alcohol with Paroxetine and Clonazepam can cause dangerous central nervous system depression, extreme sedation, respiratory suppression, and memory blackouts.
Is PAXOTIN-CR-FORTE habit-forming?
The Clonazepam component belongs to the benzodiazepine class and carries potential for dependence and tolerance when taken continuously over long periods. Clinicians typically re-evaluate the patient periodically to assess tapering strategies.
Can pregnant women take PAXOTIN-CR-FORTE?
Use during pregnancy is contraindicated unless specifically evaluated and determined to be vital by a medical specialist, as both Paroxetine and Clonazepam can pose risks to the developing fetus.
How is PAXOTIN-CR-FORTE packaged?
PAXOTIN-CR-FORTE is supplied in premium 10x10 aluminium-aluminium foil strips (100 tablets per box) manufactured with high-barrier foil to guarantee extended shelf life across all Indian climate conditions.
How can distributors apply for PCD franchise monopoly for PAXOTIN-CR-FORTE?
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Does Dellwich Lifescience offer third-party manufacturing for Paroxetine CR combinations?
Yes. Dellwich Lifescience provides turnkey contract manufacturing for Paroxetine CR + Clonazepam tablets with WHO-GMP certification, customized branding, and on-time shipment dispatch from Ahmedabad.
Where is Dellwich Lifescience headquartered?
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid logistics connections across all Indian states.
Direct Pharmaceutical Enquiry
Need Verified Information or Bulk Supply of PAXOTIN-CR-FORTE?
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Direct Manufacturer Pricing & Transparent MOQ
Exclusive PCD Monopoly Rights for Designated Districts
Fast Dispatch from Ahmedabad with GST Invoicing
Comprehensive Marketing, Visual Aids & Promotional Inputs
Quick Assistance & Orders
Enquire About PAXOTIN-CR-FORTE
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Paroxetine CR 25 mg + Clonazepam 0.5 mg Tablets.